Gary J Nabel

Summary

Publications

  1. pmc HIV integration and T cell death: additional commentary
    Arik Cooper
    Virology Laboratory, Vaccine Research Center, National Institute for Allergy and Infectious Diseases, National Institutes of Health, Bldg, 40, Room 4502, MSC 3005, 40 Convent Drive, Bethesda, MD 20892 3005, USA
    Retrovirology 10:150. 2013
  2. doi request reprint Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies
    Masaru Kanekiyo
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nature 499:102-6. 2013
  3. doi request reprint HIV-1 causes CD4 cell death through DNA-dependent protein kinase during viral integration
    Arik Cooper
    Virology Laboratory, Vaccine Research Center, National Institute for Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892 3005, USA
    Nature 498:376-9. 2013
  4. doi request reprint Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV
    Mario Roederer
    Vaccine Research Center, NIAID, NIH, Bethesda, Maryland 20892, USA
    Nature 505:502-8. 2014
  5. doi request reprint Antibodies VRC01 and 10E8 neutralize HIV-1 with high breadth and potency even with Ig-framework regions substantially reverted to germline
    Ivelin S Georgiev
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892
    J Immunol 192:1100-6. 2014
  6. ncbi request reprint Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16
    Marie Pancera
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, US National Institutes of Health, Bethesda, Maryland, USA
    Nat Struct Mol Biol 20:804-13. 2013
  7. ncbi request reprint Flow cytometry reveals that H5N1 vaccination elicits cross-reactive stem-directed antibodies from multiple Ig heavy-chain lineages
    James R R Whittle
    Vaccine Research Center, National Institute for Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    J Virol 88:4047-57. 2014
  8. ncbi request reprint Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor
    Amarendra Pegu
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases NIAID, National Institutes of Health NIH, 40 Convent Drive, Bethesda, MD 20892, USA
    Sci Transl Med 6:243ra88. 2014
  9. doi request reprint Phase I randomized clinical trial of VRC DNA and rAd5 HIV-1 vaccine delivery by intramuscular (i.m.), subcutaneous (s.c.) and intradermal (i.d.) administration (VRC 011)
    Mary E Enama
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America
    PLoS ONE 9:e91366. 2014
  10. ncbi request reprint Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies
    Tongqing Zhou
    Vaccine Research Center, National Institutes of Health, Bethesda, MD 20892, USA
    Immunity 39:245-58. 2013

Collaborators

Detail Information

Publications28

  1. pmc HIV integration and T cell death: additional commentary
    Arik Cooper
    Virology Laboratory, Vaccine Research Center, National Institute for Allergy and Infectious Diseases, National Institutes of Health, Bldg, 40, Room 4502, MSC 3005, 40 Convent Drive, Bethesda, MD 20892 3005, USA
    Retrovirology 10:150. 2013
    ..Nature 498:376-379, 2013). They have raised several hypothetical points that we further clarify here...
  2. doi request reprint Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies
    Masaru Kanekiyo
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nature 499:102-6. 2013
    ....
  3. doi request reprint HIV-1 causes CD4 cell death through DNA-dependent protein kinase during viral integration
    Arik Cooper
    Virology Laboratory, Vaccine Research Center, National Institute for Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892 3005, USA
    Nature 498:376-9. 2013
    ....
  4. doi request reprint Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV
    Mario Roederer
    Vaccine Research Center, NIAID, NIH, Bethesda, Maryland 20892, USA
    Nature 505:502-8. 2014
    ..These analyses provide insight into the limited efficacy seen in HIV vaccine trials. ..
  5. doi request reprint Antibodies VRC01 and 10E8 neutralize HIV-1 with high breadth and potency even with Ig-framework regions substantially reverted to germline
    Ivelin S Georgiev
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892
    J Immunol 192:1100-6. 2014
    ..Partial framework revertants of HIV-1 broadly neutralizing Abs may present advantages over their highly mutated counterparts as Ab therapeutics and as targets for immunogen design. ..
  6. ncbi request reprint Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16
    Marie Pancera
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, US National Institutes of Health, Bethesda, Maryland, USA
    Nat Struct Mol Biol 20:804-13. 2013
    ..Although HIV-1-glycan diversity facilitates evasion, antibody somatic diversity can overcome this and can provide clues to guide the design of modified antibodies with enhanced neutralization. ..
  7. ncbi request reprint Flow cytometry reveals that H5N1 vaccination elicits cross-reactive stem-directed antibodies from multiple Ig heavy-chain lineages
    James R R Whittle
    Vaccine Research Center, National Institute for Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    J Virol 88:4047-57. 2014
    ....
  8. ncbi request reprint Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor
    Amarendra Pegu
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases NIAID, National Institutes of Health NIH, 40 Convent Drive, Bethesda, MD 20892, USA
    Sci Transl Med 6:243ra88. 2014
    ....
  9. doi request reprint Phase I randomized clinical trial of VRC DNA and rAd5 HIV-1 vaccine delivery by intramuscular (i.m.), subcutaneous (s.c.) and intradermal (i.d.) administration (VRC 011)
    Mary E Enama
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America
    PLoS ONE 9:e91366. 2014
    ..m.) supported proceeding to a Phase 2 b efficacy study. Here we report comparison of the i.m., subcutaneous (s.c.) and intradermal (i.d.) routes of administration...
  10. ncbi request reprint Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies
    Tongqing Zhou
    Vaccine Research Center, National Institutes of Health, Bethesda, MD 20892, USA
    Immunity 39:245-58. 2013
    ..Developmental similarities in multiple donors thus reveal the generation of VRC01-class antibodies to be reproducible in principle, thereby providing a framework for attempts to elicit similar antibodies in the general population. ..
  11. pmc Prime-boost interval matters: a randomized phase 1 study to identify the minimum interval necessary to observe the H5 DNA influenza vaccine priming effect
    Julie E Ledgerwood
    Vaccine Research Center, National Institute ofAllergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Infect Dis 208:418-22. 2013
    ..This study defines the shortest prime-boost interval associated with an improved response to MIV...
  12. doi request reprint Structural and genetic basis for development of broadly neutralizing influenza antibodies
    Daniel Lingwood
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892 3005, USA
    Nature 489:566-70. 2012
    ..The data further suggest that selected immunoglobulin genes recognize specific protein structural 'patterns' that provide a substrate for further affinity maturation...
  13. pmc Gene-based vaccination with a mismatched envelope protects against simian immunodeficiency virus infection in nonhuman primates
    Lukas Flatz
    Vaccine Research Center, NIAID, National Institutes of Health, Bethesda, Maryland, USA
    J Virol 86:7760-70. 2012
    ..These data indicate that a vaccine expressing a mismatched Env gene alone can prevent SIV infection in NHPs and identifies an immune correlate that may guide immunogen selection and immune monitoring for clinical efficacy trials...
  14. pmc Comparative analysis of the magnitude, quality, phenotype, and protective capacity of simian immunodeficiency virus gag-specific CD8+ T cells following human-, simian-, and chimpanzee-derived recombinant adenoviral vector immunization
    Kylie M Quinn
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 190:2720-35. 2013
    ..Collectively, these data provide the immunologic basis for using specific rAd vectors alone or as part of prime-boost regimens to induce CD8(+) T cells for rapid effector function or robust long-term memory, respectively...
  15. doi request reprint Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning
    Peter D Kwong
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, US National Institutes of Health, Bethesda, Maryland 20892, USA
    Nat Rev Immunol 13:693-701. 2013
    ..This knowledge has provided fundamental insights into the pathways that elicit broadly neutralizing antibodies and provides a foundation for active and passive immunization strategies to prevent HIV-1 infection. ..
  16. pmc Rational design of vaccines for AIDS and influenza
    Gary J Nabel
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Trans Am Clin Climatol Assoc 123:9-15; discussion 15-6. 2012
    ..Similarly, for influenza, understanding of this target has led to structural and genetic approaches to the development of new immunogens that provide a proof of concept for universal influenza vaccination...
  17. pmc Outer domain of HIV-1 gp120: antigenic optimization, structural malleability, and crystal structure with antibody VRC-PG04
    M Gordon Joyce
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    J Virol 87:2294-306. 2013
    ..2.2 with VRC-PG04 provides atomic-level details for an HIV-1 domain recognized by broadly neutralizing antibodies and insights relevant to the rational design of an immunogen that could elicit such antibodies by vaccination...
  18. ncbi request reprint Safety and tolerability of a live oral Salmonella typhimurium vaccine candidate in SIV-infected nonhuman primates
    Alida Ault
    Laboratory Animal Medicine, Vaccine Research Center, NIAID, NIH, Bethesda, MD 20892, United States
    Vaccine 31:5879-88. 2013
    ..Based on shedding, systemic spread, and histopathology, the live-attenuated S. typhimurium strain CVD 1921 appears to be safe and well-tolerated in the nonhuman primate model, including chronically SIV-infected rhesus macaques...
  19. pmc DNA vaccine delivered by a needle-free injection device improves potency of priming for antibody and CD8+ T-cell responses after rAd5 boost in a randomized clinical trial
    Barney S Graham
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
    PLoS ONE 8:e59340. 2013
    ..DNA vaccine immunogenicity has been limited by inefficient delivery. Needle-free delivery of DNA using a CO2-powered Biojector® device was compared to delivery by needle and syringe and evaluated for safety and immunogenicity...
  20. pmc Antibody-dependent cellular cytotoxicity against primary HIV-infected CD4+ T cells is directly associated with the magnitude of surface IgG binding
    Adjoa Smalls-Mantey
    HIV Specific Immunity Section, Laboratory of Immunoregulation, NIAID, NIH, Bethesda, Maryland, USA
    J Virol 86:8672-80. 2012
    ..Increased understanding of the parameters that dictate ADCC against HIV-1-infected cells will inform efforts to stimulate ADCC activity and improve its potency in vaccinees...
  21. pmc The changing face of HIV vaccine research
    Peter D Kwong
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Int AIDS Soc 15:17407. 2012
    ..This article summarizes challenges to the development of an HIV-1 vaccine, lessons learned from scientific investigation and completed vaccine trials, and promising developments in HIV-1 vaccine design...
  22. pmc Computational prediction of N-linked glycosylation incorporating structural properties and patterns
    Gwo Yu Chuang
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MA 20892, USA
    Bioinformatics 28:2249-55. 2012
    ..None of the currently available servers, however, utilizes protein structural information for the prediction of N-glycan occupancy...
  23. pmc The need and challenges for development of an Epstein-Barr virus vaccine
    Jeffrey I Cohen
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institute of Health, Bethesda, MD 20892, USA
    Vaccine 31:B194-6. 2013
    ....
  24. doi request reprint Elicitation of broadly neutralizing influenza antibodies in animals with previous influenza exposure
    Chih Jen Wei
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 3005, USA
    Sci Transl Med 4:147ra114. 2012
    ....
  25. doi request reprint The design and evaluation of HIV-1 vaccines
    Kevin O Saunders
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 3005, USA
    AIDS 26:1293-302. 2012
    ..Together, these findings will help shape the next generation of HIV vaccines...
  26. pmc A specific domain of the Chikungunya virus E2 protein regulates particle formation in human cells: implications for alphavirus vaccine design
    Wataru Akahata
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    J Virol 86:8879-83. 2012
    ..Selected other mutations in the ASR, or changes in pH, also increased VLP yield. These results demonstrate that the ASR of E2 plays an important role in regulating particle generation...
  27. pmc Virus inhibition activity of effector memory CD8(+) T cells determines simian immunodeficiency virus load in vaccinated monkeys after vaccine breakthrough infection
    Takuya Yamamoto
    Vaccine Research Center, NIAID, NIH, Bethesda, Maryland, USA
    J Virol 86:5877-84. 2012
    ..The ability to elicit such virus-specific EM CD8(+) T cells might contribute substantially to an efficacious HIV/AIDS vaccine, even after breakthrough infection...
  28. doi request reprint Productive replication of Ebola virus is regulated by the c-Abl1 tyrosine kinase
    Mayra García
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Sci Transl Med 4:123ra24. 2012
    ..These data indicate that c-Abl1 regulates budding or release of filoviruses through a mechanism involving phosphorylation of VP40. This step of the virus life cycle therefore may represent a target for antiviral therapy...